The Second Circuit upheld the insider trading conviction of Robert Schulman, a former patent attorney at Hunton & Williams, convicted in 2017 for tipping his investment adviser, Tibor Klein, to Pfizer’s planned acquisition of King Pharmaceuticals in 2010. Schulman appealed a decision rejecting his motion to vacate his conviction on grounds of insufficient evidence. In affirming that decision, the Second Circuit concluded that the jury was not required to credit Schulman’s testimony that he intended only to brag about his knowledge of the merger to a friend.
January 10, 2019
Second Circuit upholds insider trading conviction of former lawyer
Related by Topic
New Post
Arizona resident reaches settlement with SEC to resolve insider trading charges
August 28, 2025
News Alert
New Post
SEC charges former biopharma director and his friends and relatives with insider trading
August 27, 2025
News Alert
SEC charges Dallas resident with insider trading
August 13, 2025
News Alert